Global Blood Therapeutics (GBTG) affiliate notifies SEC of 17,500‑share resale
Rhea-AI Filing Summary
Global Blood Therapeutics reported an intended sale of 17,500 shares of Class A Common Stock on a Form 144 notice. The filing lists individual entries tied to prior open‑market transactions (for example, 5,000 shares on 06/09/2022, 5,000 shares on 06/10/2022, and 5,000 shares on 11/25/2022). The filing is a routine Section 144 disclosure of proposed sales by an affiliate.
Positive
- None.
Negative
- None.
Insights
Form 144 notifies the SEC of proposed resale of restricted or control securities.
Form 144 is a statutory notice that an affiliate proposes to sell restricted or control shares; it does not itself execute a sale. The entry shows 17,500 shares of Class A Common Stock listed on the notice with dated line items.
The timing and proceeds of any actual sale are not stated in the excerpt. Subsequent Form 4 or broker reports would document completed transactions; this filing simply signals an intent to resell consistent with Rule 144 procedures.